Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Infectious Diseases

Categories

Infectious diseases are a global threat to human health as illustrated by the COVID-19 pandemic. To counter this threat further research efforts are needed to improve the ways we prevent, control and treat infectious diseases. Prevention is at the center of infectious diseases vaccine research. Control is achieved through work on infectious diseases diagnostic tests whereas infectious diseases drug discovery aims at improving our treatment options.

antibodies-online.com offers a very broad selection of reliable, validated antibodies, proteins and ELISA Kits for research on Infectious Diseases. Many of our products are being used as components in diagnostic kits - often in conjunction with our anti-human IgG and anti-human IgM antibodies. Our experts can guide you to the right antibodies and antigens for your infectious disease research and development project. Get in touch via phone, chat or email!

Infectious Disease Antibodies, Antigens and Kits

Infectious Diseases can be clustered by the type of pathogen that causes the disease. Click on a link to search our product portfolio:

Viral Diseases

(e.g. COVID-19, Influenza A, SARS)

Bacterial Diseases

(e.g. Tuberculosis, Antibiotic Resistance, Haemophilus Influenzae)

Fungal Diseases

(e.g. Drug Resistance against antifungal treatments)

Parasitic Diseases

(e.g. Diseases caused by protozoan or helminth parasites)

Viral Disease Antibodies, Antigens and Kits

Bacterial Disease Antibodies, Antigens and Kits

Fungal Disease Antibodies, Antigens and Kits

Parasitic Disease Antibodies, Antigens and Kits

Featured Infectious Disease Antibodies and Kits

Product
Reactivity
Clonality
Application
Cat. No.
Quantity
ReactivityAll Species
Clonality
ApplicationELISA
Cat. No.ABIN6574100
Quantity96 tests
ReactivitySARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2)
ClonalityMonoclonal
ApplicationCrys, ELISA, Neut, SPR
Cat. No.ABIN6952546
Quantity200 μg
ReactivitySARS Coronavirus-2 (SARS-CoV-2)
ClonalityChimeric
ApplicationGICA, ELISA, WB
Cat. No.ABIN6952664
Quantity100 μL
ReactivityRespiratory Syncytial Virus (RSV)
ClonalityPolyclonal
ApplicationIHC (p), IFA, Neut, ELISA
Cat. No.ABIN238058
Quantity1 mL
ReactivityInfluenza A Virus H1N1
ClonalityMonoclonal
ApplicationPrA, ELISA, WB
Cat. No.ABIN235631
Quantity1 mg
ReactivityInfluenza A Virus H1N1
ClonalityPolyclonal
ApplicationIHC, WB
Cat. No.ABIN1841889
Quantity100 μL
ReactivityHepatitis B Virus (HBV)
ClonalityPolyclonal
ApplicationIHC, ELISA, WB
Cat. No.ABIN285516
Quantity1 mg
ReactivityHaemophilus influenzae
ClonalityMonoclonal
ApplicationEIA, IF
Cat. No.ABIN180862
Quantity0.2 mg
ReactivityHuman, Mouse
ClonalityMonoclonal
ApplicationIF, WB
Cat. No.ABIN3200993
Quantity0.1 mg
ReactivityBorrelia burgdorferi
ClonalityPolyclonal
ApplicationIF, IHC (p), WB
Cat. No.ABIN236885
Quantity1 mL

Need Help? Call our PhD Customer Support!

  • We will help you to find the right products for your research.
  • We offer reliable antibodies, kits, proteins, lysates for Infectious Disease research.
  • Contact us via email or phone: (877) 302 8632 (US) or +49 241 95 163 153 (International)

Vaccine Development for Infectious Diseases

For emerging infectious diseases vaccine development is seen as a vital component of disease prevention. Often other medical options are unavailable or the disease results in rapid clinical deterioration that the effectiveness of drugs is limited.1 The importance of vaccines in outbreak response is underlined by the foundation of the Coalition for Epidemic Preparedness Innovations (CEPI) 2017 in the wake of the Ebola epidemic 2014/2015.2 The objective of CEPI is to ensure a coordinated effort in developing and deploying new vaccines to prevent future epidemics. During the COVID-19 pandemic CEPI is involved in numerous vaccine development projects.3

Key Vaccine Development Activities

Hatchett and Lurie point out key vaccine development activities that should be carried out both before and during the outbreak:2

  • Sequence, serotype, and share outbreak strain
  • Collect acute and convalescent blood samples and other body fluid specimens
  • Accelerate development of diagnostic tests that can serve as endpoints for vaccine trials
  • Conduct epidemiological studies essential for vaccine development
  • Understand cultures and beliefs

Vaccine Development Platforms

An antigen delivery system which optimizes antigen presentation and induces broad protective immune responses is the center piece for the development of successful and effective vaccines. A number of different vaccine platforms have been established over the years:

  • Viral Vector Technology
  • Virus-like Particles
  • Nucleic Acid Vaccines
  • Synthetic Peptides
  • Inactivated Viruses

For benefits and disadvantages of each approach see Afrough et al. (2019).1

Diagnostic Test Development for Emerging Infectious Diseases

Diagnostic tests for Infectious Diseases can serve multiple purposes, i.e. surveillance, diagnosis, and support of clinical decision making. The purpose of these diagnostic tests is to accurately identify the infecting pathogen to enable healthcare professionals to initiate appropriate treatments and prevent further transmission of disease. Given the implications the test must have sufficient clinical sensitivity and specificity to be useful. Complications in diagnostic tests such as cross-reactivity with other pathogens poses additional challenges for developing diagnostic tests for emerging infectious diseases.4

To avoid false positive results cross reactivity needs to be evaluated by testing specimens containing antibodies to other microorganisms. Selection of the relevant mircoorganisms depends on prevalance and differential diagnosis for the disease in question. As an example: For SARS-CoV-2 ELISA tests the WHO recommends cross reactivity analysis for the following organisms: Other coronaviruses (e.g. Human coronavirus OC43), Adenovirus, Human Metapneumovirus (hMPV), Parainfluenza virus, Influenza A virus, Influenza B virus, Haemophilus influenzae, Rhinovirus, Respiratory syncytial virus, Epstein-Barrvirus.

Drug Discovery for Emerging Infectious Diseases

As was the case for COVID-19 typically neither drugs nor vaccines are available at the outset of an emerging infectious disease. Repurposing drugs that have been approved for other diseases is often the fastest way to arrive at a treatment option for such a disease - as underlined by the approval of Remdesivir for the treatment of COVID-19.5

References

  • B. Afrough, S. Dowall, R. Hewson (2019) "Emerging viruses and current strategies for vaccine intervention" Clin Exp Immunol. 2019 May; 196(2): 157–166
  • Richard Hatchett, Nicole Lurie (2019) "Outbreak response as an essential component of vaccine development" The Lancet, Vol 11, Issue 11, Pages E399-E403
  • CEPI Website
  • Roberts (2019) "Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development" Hum Vaccin Immunother. 2019;15(10):2258-2263
  • Gungdi Li, Erik De Clerq (2020) "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)" Nature Reviews Drug Discovery
You are here: